FDA targets misleading supplement labels

The FDA unveiled a new set of regulations calling for supplement companies to offer "competent and reliable scientific evidence" for health claims made on packages. The move was spurred by recent health concerns surrounding two popular supplements, ephedra and androstenedione, which have already been removed from store shelves.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC